Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

See all formats and pricing
More options …
Volume 41, Issue 4


Pharmacogenomics of Drugs Affecting the Cardiovascular System

Gérard Siest / Luc Ferrari / Marie-José Accaoui / Anne-Marie Batt / Sophie Visvikis
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2003.089


The variability in drug response originates partly from genetics, with possible consequences for drug efficacy, adverse effects, and toxicity. Until now, pharmacogenetics mainly indicated the best known source of variability, that is, the variability caused by drug metabolism. However, simultaneous progress in the knowledge of biochemical targets of drugs and of the human genome, together with the development of new technologies, revealed many new sources of human genetic variation, e.g., in receptors or transporters.

Drugs are metabolized by various polymorphic phase I enzymes, including cytochromes P450 (CYP). Among them, the most relevant for the metabolism of cardiovascular drugs are CYP3A4, CYP2C9 or CYP2C19, and CYP2D6. The role of phase II enzymes is limited with regard to cardiovascular drugs biotransformation, but some polymorphisms (glutathion-S-transferase; GSH-T) are linked to cardiovascular risk. Phase III proteins or transporters, especially from the ABC family, must also be considered, as their polymorphisms affect cholesterol and other sterols transport.

Among pharmacological targets, some proteins were identified as involved in interindividual variations in the response to cardiovascular drugs. Some examples are apolipoprotein E, angiotensin-converting enzyme, and the β-adrenergic receptor.

From the risk concept emphasizing impaired metabolism and adverse effects, we now moved to an approach, which is a personalized, genotype-dependent adaptation of therapy.

About the article

Published Online: 2005-06-01

Published in Print: 2003-04-25

Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 41, Issue 4, Pages 590–599, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2003.089.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

A.C. Rodrigues, I.M.M. Rebecchi, M.C. Bertolami, A.A. Faludi, M.H. Hirata, and R.D.C. Hirata
Brazilian Journal of Medical and Biological Research, 2005, Volume 38, Number 9, Page 1389
Dominick J. Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, Celia Ramírez, Ugo Cavallari, Elisabetta Trabetti, Manel Sabaté, Pilar Jimenez-Quevedo, Rosana Hernández, Raul Moreno, Javier Escaned, Fernando Alfonso, Camino Bañuelos, Marco A. Costa, Theodore A. Bass, Pier Franco Pignatti, and Carlos Macaya
Thrombosis Research, 2005, Volume 116, Number 6, Page 491
Gérard Siest, Jean-Brice Marteau, Sandy Maumus, Hind Berrahmoune, Elise Jeannesson, Anastasia Samara, Anne-Marie Batt, and Sophie Visvikis-Siest
European Journal of Pharmacology, 2005, Volume 527, Number 1-3, Page 1
Giuseppe Lippi, Massimo Franchini, and Emmanuel J. Favaloro
Clinical Chemistry and Laboratory Medicine, 2009, Volume 47, Number 5
G Siest, E Jeannesson, H Berrahmoune, S Maumus, J-B Marteau, S Mohr, and S Visvikis
Pharmacogenomics, 2004, Volume 5, Number 7, Page 779
Comparative and Functional Genomics, 2003, Volume 4, Number 6, Page 681

Comments (0)

Please log in or register to comment.
Log in